A Phase 3 interventional study of Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) in Macular Edema, sponsored by Bayer. Completed at 64 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-07-31.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies testing aflibercept in Macular Edema — 1 open to participants now, 3 under way, 1 of them phase 3. aflibercept · Macular Edema.
Among the 53 studies testing aflibercept in Macular Edema, this one is the 4th largest by enrollment, is one of 9 that started in 2016, is one of 11 in phase 3, and was the 31st registered.
758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.
Browse Macular Edema studies →1 of the 53 studies testing aflibercept in Macular Edema is open now, in 1 country. Recruiting first, the newest first:
CMH Multan Institute of Medical Sciences · Sites in Pakistan
Ages 30–60
By country, each count listing its studies:
aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 12 · Phase 4 26
First in 2006; this study’s year is marked. 9 started in 2016.
This study's enrollment of 463 is above the median of 56 across 586 interventional studies indexed under Macular Edema.
Median enrollment 49 across the 53 interventional studies. Of the 36 that completed or were terminated, 18 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 53 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
16 studies in Macular Edema by Bayer: none open now, 1 under way, none of them phase 3. Of 15 finished, 8 (53%) have results posted.
Among the 16 studies in Macular Edema by Bayer, this one is the 3rd largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2016, is one of 7 in phase 3, and was the 10th registered.
Bayer’s Macular Edema studies by the year they started, since 2009.
1 of the studies testing aflibercept in Macular Edema that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02645266McMaster UniversityMean Visual Acuity Changes Following Five Injections of Aflibercept | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 53 studies testing aflibercept in Macular Edema, from their registry updates:
Among Bayer’s 16 in Macular Edema:
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy of long-term treatment with 2 mg aflibercept via different intravitreal (IVT) treatment regimens to participants with DME pretreated with 2 mg aflibercept every 8 weeks after 5 initial monthly injections for approximately 1 year or more (according to the EU label for the first year of treatment)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The subject's history of aflibercept treatment met all of the following:
To be met at initiation of pre-study aflibercept treatment:
Exclusion Criteria:
At initiation of pre-study aflibercept treatment:
At initiation of pre-study aflibercept treatment, screening for this study, and baseline for this study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received fixed dosing of 2 mg aflibercept at injection intervals of 8 weeks
Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Participants received flexible dosing of 2 mg aflibercept at injection intervals of ≥8 week
Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Participants received monthly monitoring with 2 mg aflibercept injection pro re nata (PRN, as needed)
Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 52
Best Corrected Visual Acuity (BCVA) was measured in the study eye by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score starting at 4 meters. The ETDRS chart includes 70 letters in total and the letter score ranges from 0 to 100. More letters read correctly results in a higher letter score, which represents better visual acuity.
Time frame: From baseline to Week 52
Mean Change From Baseline in Central Retinal Thickness (CRT) at Week 52
Central Retinal Thickness (CRT) was measured in the study eye by spectral domain optical coherence tomography (SD-OCT).
Time frame: From baseline to week 52
Number of Participants With Categorized Changes From Baseline in Best Corrected Visual Acuity (BCVA) at Week 52
Best Corrected Visual Acuity (BCVA) was measured in the study eye by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score starting at 4 meters. The ETDRS chart includes 70 letters in total and the letter score ranges from 0 to 100. More letters read correctly results in a higher letter score, which represents better visual acuity
Time frame: From baseline to week 52
Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 100
Best Corrected Visual Acuity (BCVA) was measured in the study eye by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score starting at 4 meters. The ETDRS chart includes 70 letters in total and the letter score ranges from 0 to 100. More letters read correctly results in a higher letter score, which represents better visual acuity.
Time frame: From baseline to Week 100
Mean Change From Baseline in Central Retinal Thickness (CRT) at Week 100
Central Retinal Thickness (CRT) was measured in the study eye by spectral domain optical coherence tomography (SD-OCT).
Time frame: From baseline to Week 100
Number of Participants With Categorized Changes From Baseline in Best Corrected Visual Acuity (BCVA) at Week 100
Best Corrected Visual Acuity (BCVA) was measured in the study eye by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score starting at 4 meters. The ETDRS chart includes 70 letters in total and the letter score ranges from 0 to 100. More letters read correctly results in a higher letter score, which represents better visual acuity
Time frame: From baseline to Week 100
Number of Participants With Treatment-emergent Adverse Event (TEAE)
AEs that started after the first application of aflibercept under this protocol until 30 days after the last dose of study drug administration
Time frame: Up to Week 100
Study was conducted at multiple centers in 14 countries between 16-Nov-2016 (first participant first visit) and 24-Sep-2019 (last participant last visit).
| Milestone | Aflibercept 2 mg Fixed | Aflibercept 2 mg Extended | Aflibercept 2 mg PRN |
|---|---|---|---|
| Started | 155 | 154 | 154 |
| Completed week 52 visit | 144 | 146 | 140 |
| Completed | 137 | 138 | 136 |
| Not completed | 18 | 16 | 18 |
| Withdrew: Adverse event | 3 | 2 | 1 |
| Withdrew: Lost to follow-up | 4 | 1 | 2 |
| Withdrew: Withdrawal by sponsor | 0 | 1 | 1 |
| Withdrew: Death | 3 | 6 | 8 |
| Withdrew: Withdrawal by subject | 7 | 6 | 6 |
| Withdrew: Physician decision | 1 | 0 | 0 |
Best Corrected Visual Acuity (BCVA) was measured in the study eye by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score starting at 4 meters. The ETDRS chart includes 70 letters in total and the letter score ranges from 0 to 100. More letters read correctly results in a higher letter score, which represents better visual acuity.
| Scores on a scale | Aflibercept 2 mg Fixed | Aflibercept 2 mg Extended | Aflibercept 2 mg PRN |
|---|---|---|---|
| Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 52 | 0.4 ± 6.7 | 0.5 ± 6.7 | 1.7 ± 6.8 |
Central Retinal Thickness (CRT) was measured in the study eye by spectral domain optical coherence tomography (SD-OCT).
| Microns | Aflibercept 2 mg Fixed | Aflibercept 2 mg Extended | Aflibercept 2 mg PRN |
|---|---|---|---|
| Mean Change From Baseline in Central Retinal Thickness (CRT) at Week 52 | -18.8 ± 45.5 | -2.1 ± 56.2 | 2.2 ± 77.8 |
Best Corrected Visual Acuity (BCVA) was measured in the study eye by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score starting at 4 meters. The ETDRS chart includes 70 letters in total and the letter score ranges from 0 to 100. More letters read correctly results in a higher letter score, which represents better visual acuity
| Participants | Aflibercept 2 mg Fixed | Aflibercept 2 mg Extended | Aflibercept 2 mg PRN |
|---|---|---|---|
| ≥15 letter gain | 4 | 5 | 4 |
| ≥10 letter gain | 10 | 14 | 13 |
| ≥30 letter loss | 1 | 0 | 0 |
Best Corrected Visual Acuity (BCVA) was measured in the study eye by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score starting at 4 meters. The ETDRS chart includes 70 letters in total and the letter score ranges from 0 to 100. More letters read correctly results in a higher letter score, which represents better visual acuity.
| Scores on a scale | Aflibercept 2 mg Fixed | Aflibercept 2 mg Extended | Aflibercept 2 mg PRN |
|---|---|---|---|
| Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 100 | 0.1 ± 7.2 | -0.1 ± 9.1 | 1.8 ± 9.0 |
Central Retinal Thickness (CRT) was measured in the study eye by spectral domain optical coherence tomography (SD-OCT).
| Microns | Aflibercept 2 mg Fixed | Aflibercept 2 mg Extended | Aflibercept 2 mg PRN |
|---|---|---|---|
| Mean Change From Baseline in Central Retinal Thickness (CRT) at Week 100 | -15.5 ± 64.3 | 2.3 ± 81.8 | -13.9 ± 74.4 |
Best Corrected Visual Acuity (BCVA) was measured in the study eye by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score starting at 4 meters. The ETDRS chart includes 70 letters in total and the letter score ranges from 0 to 100. More letters read correctly results in a higher letter score, which represents better visual acuity
| Participants | Aflibercept 2 mg Fixed | Aflibercept 2 mg Extended | Aflibercept 2 mg PRN |
|---|---|---|---|
| ≥15 letter gain | 3 | 4 | 6 |
| ≥10 letter gain | 10 | 17 | 22 |
| ≥30 letter loss | 1 | 2 | 2 |
AEs that started after the first application of aflibercept under this protocol until 30 days after the last dose of study drug administration
| Participants | Aflibercept 2 mg Fixed | Aflibercept 2 mg Extended | Aflibercept 2 mg PRN |
|---|---|---|---|
| Number of Participants With Treatment-emergent Adverse Event (TEAE) | 129 | 128 | 129 |
Collected over After the first application of Aflibercept under this protocol and within 30 days after the last dose of study drug administration, assessed up to Week 100.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aflibercept 2 mg Fixed | 3/155 (1.9%) | 35/155 (22.6%) | 97/155 (62.6%) |
| Aflibercept 2 mg Extended | 6/154 (3.9%) | 38/154 (24.7%) | 85/154 (55.2%) |
| Aflibercept 2 mg PRN | 8/154 (5.2%) | 37/154 (24%) | 98/154 (63.6%) |
| Event | Aflibercept 2 mg Fixed | Aflibercept 2 mg Extended | Aflibercept 2 mg PRN |
|---|---|---|---|
| Myocardial infarctionCardiac disorders | 5/155 | 0/154 | 1/154 |
| Cardiac arrestCardiac disorders | 0/155 | 3/154 | 1/154 |
| CataractEye disorders | 0/155 | 3/154 | 1/154 |
| Diabetic footSkin and subcutaneous tissue disorders | 1/155 | 1/154 | 3/154 |
| Diabetes mellitusMetabolism and nutrition disorders | 3/155 | 0/154 | 1/154 |
| Acute myocardial infarctionCardiac disorders | 1/155 | 2/154 | 2/154 |
| Cardiac failureCardiac disorders | 1/155 | 2/154 | 2/154 |
| Cardiac failure congestiveCardiac disorders | 0/155 | 2/154 | 0/154 |
| PneumoniaInfections and infestations | 1/155 | 2/154 | 2/154 |
| AngiocardiogramInvestigations | 0/155 | 2/154 | 0/154 |
| Event | Aflibercept 2 mg Fixed | Aflibercept 2 mg Extended | Aflibercept 2 mg PRN |
|---|---|---|---|
| CataractEye disorders | 27/155 | 29/154 | 24/154 |
| Visual acuity reducedEye disorders | 25/155 | 22/154 | 22/154 |
| Diabetes mellitusMetabolism and nutrition disorders | 24/155 | 10/154 | 15/154 |
| Diabetic retinopathyEye disorders | 14/155 | 14/154 | 18/154 |
| Macular oedemaEye disorders | 8/155 | 11/154 | 17/154 |
| NasopharyngitisInfections and infestations | 14/155 | 14/154 | 17/154 |
| Diabetic retinal oedemaEye disorders | 12/155 | 13/154 | 14/154 |
| Cystoid macular oedemaEye disorders | 14/155 | 12/154 | 10/154 |
| MaculopathyEye disorders | 3/155 | 1/154 | 13/154 |
| Intraocular pressure increasedInvestigations | 11/155 | 4/154 | 11/154 |
Safety analysis set (SAF): included all participants who received any study drug under the protocol.
| Age, Continuous(Years) | Aflibercept 2 mg Fixed | Aflibercept 2 mg Extended | Aflibercept 2 mg PRN | Total |
|---|---|---|---|---|
| Mean | 64.3 ± 8.7 | 64.8 ± 10.1 | 65.4 ± 9.3 | 64.8 ± 9.4 |
| Sex: Female, Male(Participants) | Aflibercept 2 mg Fixed | Aflibercept 2 mg Extended | Aflibercept 2 mg PRN | Total |
|---|---|---|---|---|
| Female | 55 | 59 | 64 | 178 |
| Male | 100 | 95 | 90 | 285 |
| Ethnicity (NIH/OMB)(Participants) | Aflibercept 2 mg Fixed | Aflibercept 2 mg Extended | Aflibercept 2 mg PRN | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 4 | 7 |
| Not Hispanic or Latino | 144 | 142 | 142 | 428 |
| Unknown or Not Reported | 10 | 10 | 8 | 28 |
| Race (NIH/OMB)(Participants) | Aflibercept 2 mg Fixed | Aflibercept 2 mg Extended | Aflibercept 2 mg PRN | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 2 | 1 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 | 1 |
| White | 141 | 144 | 147 | 432 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 11 | 9 | 7 | 27 |
| Best Corrected Visual Acuity (BCVA)(Scores on a scale) | Aflibercept 2 mg Fixed | Aflibercept 2 mg Extended | Aflibercept 2 mg PRN | Total |
|---|---|---|---|---|
| Mean | 72.8 ± 10.38 | 72.5 ± 11.35 | 71.0 ± 10.87 | 72.1 ± 10.88 |
| Central Retinal Thickness (CRT)(Microns) | Aflibercept 2 mg Fixed | Aflibercept 2 mg Extended | Aflibercept 2 mg PRN | Total |
|---|---|---|---|---|
| Mean | 289.8 ± 66.46 | 285.3 ± 76.01 | 294.5 ± 80.72 | 289.9 ± 74.55 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2016 to primary completion in Nov 2018, 23 months.
Results were first posted in Dec 2019, 1 year after primary completion.
Of 52 industry-sponsored phase 3 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 33. This study's 23 months is close to that.
Counting every sponsor, half of 65 studies reached it within 25 months; a quarter within 18 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept